Key facts
- It has raised $1.0B across 1 recorded rounds; the latest was Buyout/LBO (Add-on)† ($1.0B) in May 2025.
- 3 institutional filers report fund marks on Ajinomoto Bio-Pharma across 17 filings.
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Ajinomoto Bio-Pharma
Create free account
No card required
Funding rounds
1 roundsMay 2025Buyout/LBO (Add-on)†$1.0B▮
About Ajinomoto Bio-Pharma
- Industry
- Other Pharmaceuticals and Biotechnology
PA Mark — not yet priced
Ajinomoto Bio-Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Ajinomoto Bio-Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
3 filers · latest Jun 20263 SEC-registered funds reported 17 fair-value marks on Ajinomoto Bio-Pharma between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.